You are here

Home » Content

Yeni Periton Diyaliz Solüsyonları

New Peritoneal Dialysis Solutions

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2007
Author NameUniversity of AuthorFaculty of Author
Bookmark/Search this post with
Abstract (Original Language): 
Peîitori diyalizi (PD), son dönem böbrek yetmezliği tedavisinde önemli bir tedavi seçeneğidir. Tedaviye yeni başlanan hastalarda ilk yılda, yerine göre, hemodiyalizden daha üstün yönleri v ardır (1-3). Son 30 yılda ekle edilen bütün olumlu gelişmelere rağmen, teknik komplikasyon oranı PD hastalarında hâlâ yüksektir. Diyaliz tedavisi, yarı geçirgen bir membran aracılığıyla kan ve diyaliz solüsyonu arasında sıvı-so-lüt değişimi esasına dayanır. Yarı geçirgen membran ve diyaliz solüsyonu tedavinin en önemli bileşenleridir. Periton diyalizi tedavisinde hastanın kendi periton dokusu yan geçirgen membran görevini üstlenir. Tedavinin uzun dönemde başarılı olabilmesi için periton membranının yapısal ve fonksiyonel özelliklerinin korunması gerekir. Bununla beraber, standart PD solüsyonlarının kullanıldığı bir tedavide, süre uzadıkça periton membranının yapısal ve fonksiyonel özelliklerinin değişebildiği gözlenmiştir (4). Meydana gelen yapısal değişiklikler arasında interstisyel fibrozis, mezotel ve damar duvarı bazal membrankırında reduplikasyon, damar duvarı media tabakasında hyalinizasyon ve ne-oanjiyogenezis sayılabilir (4). Yapısal değişikliklerin, bugün için bilinen, en belirgin klinik yansıması, ultraliltrasyon kapasitesinde sonradan ortaya çıkan azalmadır. Periton membranında meydana gelen değişikliklerin nedeni olarak en çok standart periton diyalizi solüsyonlarının biyoııyumsuz özellikleri suçlanmıştır.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_16_pp_57-61.pdf
  • 1
57-61
  • Turkish

REFERENCES

References: 

1. Thodis E, Passadakis P, YargemezİH v, et al.
Peritonea
l dialysis: better than, equal to, or worse Ihan hemodialysis? Ferit Dial Int 2001;21< 1 >:25-35.
2. Fenton SS, Sehaubel DE, Desnieules M. el al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rales. Am.) Kidney Dfci 1997;30(3):334-42.
3. Majorca K. Cancarini G, Zubani K. ct al. CAP!) viability: a long-term comparison with hemodialysis. Perit Dial Int 1996;16:276-87.
i lie Vriese AS; Murtier S, Lameire Nil. What happens to peri¬toneal membrane in tölıg-term peritoneal dialysis? Peril Dial Int 200I;2KSuppl 3>:S35-S40.
5. Xweers MM. de Waart OK. Sinil W, et al. Growth factors VF.GF and TGP-bl in peritoneal dialysis. J Lab Clin Med 190:134:124-132.
(>. Wang T, Chen YG. Ye RG. et al. Effect of glucose on TGF-]>elal expression in peritoneal mesoihelial cells. Adv Perit Dial 1995;11:7-10.
Rang DM. Hong VS. Lim HI. el al. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-lx'tal of human peritoneal mesothelial cells:
effect of cytokine costimulation. Perit Dial Int 1999;19:221-30. 37.
8. Breborowicz A. Rodela H. Üreopoıılos DG. Toxicity of osmotic solutes on human mesothelial cells in-vitro. Kidney Int 1992;41:1280-1285.
9. Gotloib L, Waisbn.it V, Shostak A, et al. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose enriched, laclate buffered dialysis solution. Nephron 1995:70:466-477.
10. Witowski J, Jorres A. Korybalska K et al. Glucose degradation products in peritoneal dialysis fluids: do they harm? Kidney Int Suppl 2003;84;S148-S 151.
11. Jörres A, Bender TO. Witowski J. Glucose degradation products and the peritoneal mesothelium. Peril Dial Ini 2000;20(Suppl 5):S19-22.
12. Holmes CJ, Shockley 'Hi. Strategies to reduce glucose exposure in peritoneal dialysis patients. Peril Dial Int 2000;20(Suppl 2):S37-41.
13. Kippe B, Simonsen O. Heimhurger O. et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59U):348-57.
14. Honda K, Nitta K. Horita S, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999;14:1541-9.
15. Wieslander A, Linden T, Musi B, et al. Biological significance of reducing glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 2000;2(KSuppl 5):S23-7.
16. Nakayama M, Kawaguchi Y, Yamada K. et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51(l):182-6.
17. Pischetsreider M. Chemistry of glucose and biochemical palhways of biological interest. Perit Dial Int 2000;20(Suppl 2):S26-S30.
18. Grodstein GP, Bhimenkrantz MJ, Kopple JD, et al. Glucose-absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981;19:564-7.
19. Ramos JM, Heaton A. McGurk JG, et al. Sequential changes in serum lipids and their subtractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1983;35:20-30.
20. Topley N, Coles GA, Williams JD. Biocompalibility studies on peritoneal dialysis. Perit Dial Int 1994;l4 (Suppl 3>:S21-S28,
21. Devuyst O, Topley N, Williams JD. Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions, Nephrol Dial Transplant 2002; 17 (Suppl. 3);S12-SI5.
22. Davies SJ, Phillips L. Naish PF, et al. Peritoneal glucose exposure and changes in membrane solute transport with lime on PD. J Am Soc Nephrol 2001;12:1046-1051.
23- Mctntyre CW. Update on peritoneal dialysis solutions Kidney Int 2007;71:486-490.
24. Alsop RM. History, chemical, and pharmaceutical development of icodextrin. Perit Dial Int 1994;14 (Suppl 2);S5-12.
25. Ho-dac-Pannekeet MM, Schouten N. Langedijk MJ et al. Peritonea] transport characteristics with glucose polymer based dialysate. Kidney Int 1996;50:979-986.
26. Davies SJ. Kinetics of icodextrin. Perit Dial Int 1994;14(Suppl 2):S45-50.
27. Mistry CD, Gokal R, Pers E and the MIDAS study group. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994;46:496-503.
60
Türk Nefroioji Diyaliz ve Transplantasyon Dergisi
/Official
Journal of the Turkish Society of Nephrology
Yeni Periton Diyaliz Solüsyonları £
28. Garcia-Lopez E, Lindholm li. Tranarus A. Biocompatibility of new peritoneal dialysis solutions: clinical experience Perit Dial Int 2OO0;2Ot Suppl 5>:S-ı8-5<>.
1') Banc DP, Chen C, Cooker L, et al. Decreased in vitro fomia-tion ot AG Ex with extraneal solution compared to dextrose-containing peritoneal dialysis solutions. Adv Perit Dial 1999;15:12-16.
30. Cooker l.A, Choo CG, Luneburj; P. et al, Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Peril Dial 1999; 15:17-20.
31. Bajo MA. Sclgas It, Castro MA, et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int »000:2IH6>:742-7.
32. Lee III. Heddy DK, Saran It. el al. Advanced glycosylation end-products in diabetic rats mi peritoneal dialysis using various solutions. Peril Dial Ini 2:174-80.
35. Woodr**w G. Stables G. Oldroyd B. el al. Comparison of Icodextrin and glucose solutk>rts lor the daytime dwell in automated peritoneal dialysis, Nephrol Dial Transplant l999;i4X6M530-5.
36. Mislry CD, Gokal K. The ust.' of glucose polymer (icodextrin) in peritoneal dialysis: an overview. Perit Dial Int lWi;l itSuppI 3):S158-6l.
37. Gokal It, Mistry CD, Peers E, and the MIDAS study group. A United Kingdom multicenter study of icodextrin in continuous ambulatory peritoneal dialysis. Perit Dial hit l994;14(Suppl 2):S22-7.
38. Gokal K, Mistry CD, Peers F. and the MIDAS study group. Peritonitis occurrence in a muIlk enter study of icodextrin and glucose in CAPD. Peril Dial Inl 1995;15:226-30.
39. Wilkie M. Plant M, Edwards L. el al Icodextrin 7.5% dialysate solution (jducuse polymer) in p.uiL-ni- with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997;17:84-6.
40. Douma CE, Ihralall JK, tie Waart DH. et al. Icodextrin with nitroprusside increases ullrafillralion and peritoneal transport during long CAPD dwells. Kidney Int 1998;53:1014-21.
41. Jones MR, Martis L, Algrim CE, et al. Amino acid solutions for
CAPD-rationale and clinical experience. Miner Electrolyte Metab 1992;18:309-15.
42. Jones M, Hagen T, Boyle CA, et al. Treatment ol malnuıriıion with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 1998;32(5t:761-9.
43. Lo WK. Effect of PD Solutions on Patient Outcome, hi; Peritoneal Dialysis: A Clinical Update. Ronco C, Dell' Aquila R, Rodighiero MP (eds). Contrih. Nephrol. Basel Karger. 2006, vol 150, pp 90-96.
44. Trananis A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The Bicarbonate/Lai tale Study Group. Peril Dial Int 20O0;20(5):516-23.
45. Williams JD. Topley N, Craig KJ, et al. The Hurobalance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-418.
46. Jones S, Holmes CJ, Krediet RT, et al. Bicarlionate/laelate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001;59(4);1529-38.
47. Jones S, Holmes CJ, Krediet RT et al. and the hicarhonate/lac-tate study group. Continuous diaiysis with bicarbonate/lac-tate based peritoneal dialysis solution is associated with an increase in dialysate CA125 and a decrease in hyaluronic acid levels. Kidney Int 2001;59:1529-153H.
48. Cooker LA, Luneburg P. Holmes CJ, et al. Intcrleukin-d levels decreases in effluent from patients dialy/.ed with bicarbonate/lactate-based peritoneal dialysis solutions. Peril Dial Int 2001;21 (supll 3):S102-S107.
49. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits, Perit Dial Int 2000;20:216-223-
50. Topley N, Kaur D, Petersen MM, et al. In vitro effects of bicarbonate antl bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996;7(2):218-24.
51. Holmes CJ. Pre clinical biocompatibility testing of peritoneal dialysis solutions. Peril Dial Int 2000;2(HSuppl 5):S5-9.
52. le Poole CT. Wellen AG, Weijmer MC. el al. Inilialing CAPD with a regimen low in glucose and glucose degardation products, with icodextrin and aminoacids (NFPPl is safe and efficacious. Perit Dial Int 2005, 25 (Suppl 3):S64-S68,
53. Biesen WV, Boer W, Greve BD, et al. A randomized clinical trial with a 0.6% aminoacid/1.4% glycerol peritoneal dialysis solution. Perit Dial Int 2004;24:222-230.

Thank you for copying data from http://www.arastirmax.com